TScan Therapeutics (TCRX) Stock: Buy, Sell, or Hold?
TCRX - TScan Therapeutics, Inc. Common Stock
$0.32
0.00 (0.79%)
▲
5d:
-13.62%
30d:
-58.55%
90d:
-65.32%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 11, 2026
0d
Get Alerted When TCRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: TCRX is down 13.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: TCRX is down 13.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: TCRX is currently trading at $0.32, which is considered oversold relative to its 30-day fair value range of $0.48 to $0.85.
Technical Outlook: Technically, TCRX is in a strong downtrend. Immediate support is located at $0.31, while resistance sits at $0.78.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $2.67 (+732.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, TCRX is in a strong downtrend. Immediate support is located at $0.31, while resistance sits at $0.78.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $2.67 (+732.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.48 -
$0.85
Company Quality Score
46/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
82.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 732.3% below Wall St target ($2.67)
- WARNING: Composite score 46/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.48 -
$0.85
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.31
Resistance Level
$0.78
Current Trend
Strong Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.56
Wall Street Target
$2.67
(+732.3%)
Revenue Growth (YoY)
-65.8%
Share & Embed Analysis
Last updated: September 12, 2026 11:46 PM ET
Data refreshes hourly during market hours. Next update: 12:46 AM
Data refreshes hourly during market hours. Next update: 12:46 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TCRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 54 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 44 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 53 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$86 | 46 HOLD |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$22 | 48 HOLD |
